Medacta International announces the acquisition of Balgrist CARD Ltd.

This acquisition is an important step to further develop combinations of products and services that will drive the evolution of the medical world in the field of Personalized Medicine.

Medacta and Balgrist have signed a four-year collaboration agreement in the field of Personalized Medicine to explore additional unmet clinical needs in orthopaedics.

November 2, 2018

CASTEL SAN PIETRO, Switzerland - Medacta International, the privately held, family-owned global developer of innovative joint, spine, and sports medicine surgical products, is proud to announce the acquisition of Balgrist CARD Ltd., an expert center for Computer Assisted Research & Development (CARD) of surgical treatments, as a spin-off from the Balgrist University Hospital in Zurich. The parties have agreed to not disclose the purchase price.

"This acquisition is an important step to further develop combinations of products and services that will drive the evolution of the medical world in the field of Personalized Medicine" said Francesco Siccardi, CEO of Medacta International. "Our innovation started with MIS techniques and ranges up to Personalized Medicine solutions based on a deep understanding of the human body, advanced kinematic models, 3D planning tools and Personalized Instruments for Patient Specific Solutions".

"During the last years at the Balgrist CARD we've developed a proprietary solution to plan and execute complex osteotomy addressing all the cases in the best way for each single patient", said Professor Christian Gerber, Chair of the Board, Balgrist CARD Ltd.

Balgrist and Medacta enter into additional collaboration agreement
On top of the Balgrist CARD acquisition, Medacta and Balgrist have signed a four-year collaboration agreement in the field of Personalized Medicine to explore additional unmet clinical needs in orthopaedics. "We strongly believe that Personalized Medicine is going to be the future in orthopaedics and we are glad to be able to collaborate with Balgrist University Hospital and the Balgrist Campus to develop products and services that will deliver to each patient the best possible solution", concluded Francesco Siccardi.

Interdisciplinary approach to the development of state-of-the-art solutions
With the Balgrist Campus, a structure has been established in which researchers, physicians, developers and the industry work together to cover all aspects of translational medicine. After the identification of a medical problem by a scientifically interested physician, the problem is investigated in collaboration with researchers and developers, and a product or service is developed to enable better or novel treatment through the establishment of a new start-up, such as Balgrist CARD AG. The spin-off sale to industry enables full commercial advancement of the solutions. The sale of Balgrist CARD AG to Medacta demonstrates a closing of the circle, from joint development of a highly efficient treatment method, to culmination with true industrial development.

About Balgrist Group
The Swiss Balgrist Association, holding of the Balgrist Group, is committed to promoting the health of people suffering from musculoskeletal disorders through the Balgrist University Hospital. The Balgrist University Hospital is a highly specialized competence center for the diagnosis, treatment and aftercare of damage to the musculoskeletal system. From a medical point of view, the range of services is divided into the fields of orthopaedics, paraplegiology, rheumatology and physical medicine, sports medicine, pediatric orthopaedics, chiropractic, radiology and anaesthesiology. Within the Balgrist Group, the Balgrist Campus, a research infrastructure of national importance, enables cutting-edge research in the field of musculoskeletal system. Balgrist Beteiligungs AG, with its unique range of capital, know-how and expert network, offers the ideal conditions for start-ups focusing on the musculoskeletal system. Balgrist CARD AG is a start-up from Balgrist. Discover more about Balgrist at www.balgrist.ch.

About Medacta International
Medacta® International is a world leading company, developer and supplier, specializing in joint replacement, spine surgery, and sports medicine solutions. Medacta's revolutionary approach and responsible innovation, focusing on Minimally Invasive Solutions and Personalized Medicine, have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, operates in over 30 countries around the globe, and employs more than 930 people. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter and LinkedIn.

Media Contact for Medacta International
media@medacta.ch